Compare Keysight Technologies Inc (KEYS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Organon & Co. Common Stock — how do they compare? Keysight Technologies Inc trades at $353.39 (market cap $63.03B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Keysight Technologies Inc is far larger — about 17.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 57 Days and Organon & Co. Common Stock for 0 Days on average.
| KEYS | OGN | |
|---|---|---|
Market Cap | $63.03B | $3.62B |
Volume | 1,168,526 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $387.90 | $13.81 |
52-Week Low | $162.19 | $5.70 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $63.17B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $357.59, down 5.32% over 24 hours, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue for 2025 reached $5.38 billion, with a net income margin of 15.81%. Recent news highlights growth in AI infrastructure and 6G testing solutions.
The outlook remains positive with a consensus price target of $421.29, implying significant upside. Risks include elevated valuation multiples and supply constraints affecting near-term revenue conversion. Institutional sentiment is bullish, with 81% of analysts rating the stock a buy.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
